Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study

Thrombosis Journal

Table 3 Univariate and multivariate adjustment analysis for predictors of the clinically relevant events

	PE with/without DVT				DVT
Variables	Univariate analysis HR (95% CI)	P-Value	Multivariable analysis HR (95% CI)	P-Value	Univariate analysis HR (95% CI)	P-Value	Multivariable analysis HR (95% CI)	P-Value
Age ≥ 75 years	0.76 (0.43–1.35)	0.35			1.55 (1.03–2.32)	0.036	1.22 (0.73–2.03)	0.44
Female	0.61 (0.36–1.03)	0.06			0.81 (0.54–1.22)	0.32
Body weight < 50 kg	1.50 (0.83–2.70)	0.18			1.92 (1.26–2.94)	0.003	0.59 (0.34–1.03)	0.06
CrCL < 50 mL/minute	0.73 (0.35–1.54)	0.41			2.46 (1.61–3.74)	0.025	2.02 (1.20–3.42)	0.008
Diabetes	1.10 (0.52–2.31)	0.81			0.65 (0.30–1.39)	0.27
Chronic heart and lung disease	2.11 (0.96–4.65)	0.06			2.00 (0.87–4.57)	0.10
Active cancer	4.55 (2.72–7.62)	< 0.001	5.19 (2.85–9.47)	< 0.001	3.84 (2.53–5.82)	< 0.001	4.12 (2.65–6.38)	< 0.001
Asymptomatic	1.61 (0.83–3.12)	0.16	1.44 (0.74–2.81)	0.29	0.95 (0.62–1.46)	0.82	1.13 (0.56–1.78)	0.58

Clinically relevant events were evaluated as a composite outcome, in which each component (recurrent VTE, acute coronary syndrome, ischemic stroke, death from any cause, and major bleeding events) was weighted equally. CI Confidence interval, CrCL Creatinine clearance, DVT Deep vein thrombosis, HR Hazard ratio, PE Pulmonary embolism

ISSN: 1477-9560